Primary Sclerosing Cholangitis Market Poised for Transformation Through 2034

DelveInsight’s latest analysis highlights a steadily evolving outlook for the Primary Sclerosing Cholangitis market across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. According to DelveInsight, the Primary Sclerosing Cholangitis market size in 2023 was highest in the United States, accounting for approximately USD 80 million, and is expected to expand further by 2034, supported by increasing disease awareness, rising diagnosed prevalence, and the anticipated launch of novel disease-modifying therapies.

Primary Sclerosing Cholangitis is a rare, chronic, and progressive cholestatic liver disease characterized by inflammation, fibrosis, and stricturing of the bile ducts, which can ultimately lead to cirrhosis, liver failure, and the need for liver transplantation. Despite decades of research, Primary Sclerosing Cholangitis remains an area of high unmet medical need due to the lack of approved therapies that can effectively halt or reverse disease progression.

Rising Primary Sclerosing Cholangitis Patient Population Across the 7MM

DelveInsight projects that in 2023, there were approximately 54,400 diagnosed cases of Primary Sclerosing Cholangitis across the 7MM, and this figure is anticipated to rise steadily through 2034. The increasing patient pool is largely attributed to improved diagnostic awareness, better access to hepatology specialists, expanded use of advanced imaging techniques such as MRCP, and the development of patient registries that enhance disease recognition and reporting.

In 2023, the United States accounted for the highest diagnosed Primary Sclerosing Cholangitis prevalence, with nearly 31,000 cases, reflecting both a larger population base and more robust diagnostic infrastructure. Among European countries, Germany recorded the highest Primary Sclerosing Cholangitis prevalence, with approximately 5,000 diagnosed cases, followed by the United Kingdom, while Spain reported the lowest prevalence at around 0.1 thousand cases. Japan accounted for approximately 3,000 diagnosed Primary Sclerosing Cholangitis cases, representing nearly 5% of the total 7MM prevalence.

Gender-based analysis reveals a higher disease burden among males. In the US alone, male Primary Sclerosing Cholangitis prevalence reached approximately 21,000 cases in 2023, compared to around 10,000 cases in females, highlighting a notable gender disparity that continues to shape epidemiological trends. Additionally, symptom-based segmentation indicates that Primary Sclerosing Cholangitis often remains asymptomatic in its early stages; in Japan, for instance, 62% of diagnosed Primary Sclerosing Cholangitis patients were asymptomatic in 2023, underscoring the importance of vigilant monitoring and early detection strategies.

Primary Sclerosing Cholangitis Market Size and Regional Dynamics

DelveInsight estimates that the United States accounted for nearly 69% of the total Primary Sclerosing Cholangitis market size across the 7MM in 2023, reinforcing its position as the dominant market. This leadership is driven by higher diagnosis rates, greater healthcare expenditure, wider access to specialty care, and ongoing clinical research activity.

Among European markets, Germany led with a Primary Sclerosing Cholangitis market size of nearly USD 8 million in 2023, while Spain represented the smallest market, valued at approximately USD 0.2 million. Japan’s Primary Sclerosing Cholangitis market size was estimated at USD 4 million, accounting for roughly 4% of the total 7MM Primary Sclerosing Cholangitis market.

Looking ahead, DelveInsight anticipates that the Primary Sclerosing Cholangitis market will undergo significant transformation during the forecast period (2024–2034), particularly with the potential approval and uptake of emerging therapies such as HTD1801 and PLN-74809 (bexotegrast). These candidates have the potential to expand the treatable patient population beyond symptomatic and supportive care, thereby increasing overall market value.

Current Primary Sclerosing Cholangitis Treatment Landscape: High Unmet Medical Need

The Primary Sclerosing Cholangitis treatment landscape remains largely supportive and multimodality-based, requiring management by specialized hepatology teams. Currently, no therapy has been conclusively proven to modify the natural course of the disease. As a result, treatment focuses on managing symptoms, preventing complications, and addressing advanced disease through liver transplantation.

High-dose ursodeoxycholic acid (UDCA) is commonly used in clinical practice due to observed trends toward improved survival, although its disease-modifying benefit remains controversial. Endoscopic interventions are employed to manage dominant bile duct strictures, while liver transplantation remains the only definitive therapeutic option for patients with advanced or end-stage disease.

Symptomatic management plays a crucial role in improving quality of life, particularly for patients experiencing severe pruritus. First-line therapies include cholestyramine, a bile acid sequestrant, which remains the only drug specifically approved for pruritus associated with partial biliary obstruction in the US. Off-label options such as rifampicin, opioid antagonists (naltrexone, naloxone), and selective serotonin reuptake inhibitors (SSRIs) are also utilized in refractory cases.

Despite these interventions, current strategies are insufficient to address the long-term disease burden of Primary Sclerosing Cholangitis, reinforcing the urgent need for innovative therapies that can target underlying fibrotic and metabolic mechanisms.

Expanding Primary Sclerosing Cholangitis Pipeline Signals a Paradigm Shift

The absence of effective disease-modifying therapies has historically constrained the Primary Sclerosing Cholangitis market. However, renewed research momentum and a growing pipeline of innovative agents signal a potential paradigm shift in the coming decade.

Among the most promising candidates is PLN-74809 (bexotegrast), developed by Pliant Therapeutics, Inc. Bexotegrast is an oral, small-molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins, which play a key role in activating TGF-β, a central driver of fibrosis. By blocking these integrins, bexotegrast aims to halt or slow fibrotic progression in Primary Sclerosing Cholangitis.

In July 2024, Pliant Therapeutics reported positive 24-week data from the 320 mg cohort of the INTEGRIS-Primary Sclerosing Cholangitis Phase IIa clinical trial, a multinational, randomized, double-blind, placebo-controlled study in patients with Primary Sclerosing Cholangitis and suspected moderate to severe liver fibrosis. The 320 mg treatment group met its primary safety endpoint, demonstrating that bexotegrast was well tolerated for up to 40 weeks of treatment. Importantly, incidences of pruritus and cholangitis were lower in the bexotegrast group compared to placebo, consistent with earlier findings. These results further strengthen the clinical profile of bexotegrast and support its continued development as a potential disease-modifying therapy.

Another key pipeline candidate is HTD1801, developed by HighTide Therapeutics. HTD1801 is a first-in-class oral lipid modulator, composed of an ionic salt of berberine and ursodeoxycholic acid, designed to reduce liver fat and improve metabolic dysfunction. The drug has completed a Phase II trial in Primary Sclerosing Cholangitis and has received both Orphan Drug Designation (ODD) and Fast Track Designation (FTD), highlighting its potential clinical and commercial significance.

According to DelveInsight, HTD1801 is expected to launch in the United States by 2027, followed by EU4 and the UK by 2028, and Japan by 2029. If approved, HTD1801 could significantly reduce disease burden and reshape the Primary Sclerosing Cholangitis treatment market during the forecast period.

Robust Clinical Research and Industry Commitment

Over the past decades, multiple pharmacotherapies, including immunosuppressants and antibiotics, have been evaluated for Primary Sclerosing Cholangitis with limited success. However, the current wave of next-generation therapies reflects renewed commitment from both industry and academic stakeholders to address the complex pathophysiology of Primary Sclerosing Cholangitis.

DelveInsight’s analysis highlights increasing clinical trial activity across Phase I, II, and III stages, with a growing focus on fibrosis inhibition, metabolic modulation, and immune-mediated mechanisms. These efforts are supported by strategic collaborations, licensing agreements, and targeted investment in rare liver diseases.

Primary Sclerosing Cholangitis Epidemiology and Comorbidity Insights

Primary Sclerosing Cholangitis is frequently associated with inflammatory bowel disease (IBD), particularly ulcerative colitis. DelveInsight estimates that in 2023, approximately 23,000 Primary Sclerosing Cholangitis cases in the United States were associated with IBD, and this number is expected to increase over the forecast period. This strong comorbidity link has important implications for diagnosis, disease monitoring, and treatment strategies.

Primary Sclerosing Cholangitis Market Outlook Through 2034

According to DelveInsight, the Primary Sclerosing Cholangitis market across the 7MM is expected to evolve substantially between 2020 and 2034, driven by epidemiological growth, increased diagnosis, and the potential introduction of disease-modifying therapies. While liver transplantation will remain a cornerstone for advanced disease, emerging drugs such as HTD1801 and bexotegrast could expand therapeutic options earlier in the disease course.

The anticipated uptake of HTD1801, for example, is expected to be moderate, with a projected peak market share of approximately 15% in the US, reached over a seven-year period following launch. Such uptake patterns reflect cautious adoption in a rare disease market, balanced against strong unmet need and the absence of alternatives.

About the Report

DelveInsight’s “Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive overview of the Primary Sclerosing Cholangitis landscape, including historical and forecasted epidemiology, treatment practices, emerging therapies, market size and share analysis, SWOT assessment, reimbursement scenarios, and key opinion leader (KOL) insights across the United States, EU4 and the UK, and Japan.

The report is designed to support pharmaceutical companies, investors, policymakers, and healthcare stakeholders in understanding the evolving Primary Sclerosing Cholangitis market and identifying strategic opportunities in this high unmet need space.